Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma

NCT05283720 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT05283720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05283720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
Lead sponsor
Genmab
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 14, 2022
Completion date
November 30, 2032
Enrollment
264 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma